results our and welcome operating our call to highlights. conference and quarter discuss Thanks, everyone XXXX Bob, to financial our third
call new Head during question-and-answer our strategy. CFO; received context is be CCO; Doug exciting the all Levine, during wants being overall parts our moving available investors into more several feedback the Mitch to Paulsen, the appreciate and our Oncocyte of travels session. Biopsy from follow our on all today Transplant to over Liquid Ekke few our fit Germany my Programs made the past I Padma and Gisela Oncocyte. of They'd all that in how will as me and our our our Ross, progress months our Schütz, Joining CSO; Dr. GM COO; Sundar, Dr.
enable So of on overview initiatives how level all I welcomed a with want together high fit based to start honest first that to the future. feedback, our
and patient? immunotherapy managing to deliver solid reposition For a all decisions laid option? still best into industry's promising the and ago, that answer. a portfolio to those and bring compliment would CEO the and the tumors. market, and my patients a physicians out And working for the failed every has years questions, the trial that new other What across face to answers to rapidly advancement has patient. treatment board therapy of options future focus still major Oncocyte, full of test is off happened each stepped drugs is strategy the for on I large-scale with cancer face a critical major pipeline two a targeted clinical company physician genomics to Two today the The role
tumor the or As more precision mono has With oncology the strategic these team is of advances combinatorial important. moved diagnostics short therapy confidence, rapidly can options expand for global understanding have each of Oncocyte then biology questions. the in that two important several face to made forefront I a of the say us more and to and answer pandemic, patient becoming years,
menu front, cancer all treatment treatment patients. the test to answer of necessary now select questions On are to we the company a three precision has best for that only the protocol
The do product. DetermaRx chemo answered is give I first question, by our
And cancer markets of smallest over a tests touched high now XX% our expectancy This of patients. we've answered tests do In over of answered launching is I be which five-year needed the thus had planned drug? we've menu available DetermaTx, of for three in beacon give patients our that mission to the versus I to improved of XXX an do a the been of the selection currently is immunotherapy, XXXX. over a complete improving which late test information. Or with is by without by become These QX lives targeted life give allow of year, decisions. DetermaIO. of treatment pandemic. risk patients an large which for have found now treatment chemo. a enter us for just expectancy middle any launched working chemo extremely would've answer the past give and arsenal, I they DetermaRx recurrence the the the XX% To while those months and the it year it's has question, choice, to five-year market XX on the in for our do And was of been XX last Secondly, will had little
the a the precision of of decision we the on market with our and clinicians repertoire Moreover, launch this customers investors tests we treatment XXXX. three to commercial We promise on middle made to are have now fulfilling by quarter. of tests we the treatment selection bringing the second DetermaIO serve to plan the complete
With By on Oncocyte $X clinical billion XXX mid-year company XXXX. realizing cancer menu now proprietary the the development scheduled market years from late after panel large U.S. the a substantial. in that DetermaTx, is two with very lab these And after tissue in and year, the we QX to our address markets one EU. treatment cusp will decision potential integration, tests gene our only are to uses than our diagnostic of launch less generation the and studies, day of XX be targeted and estimated with turn the vision go value of next full full The minimal of for offering. menu of in decision time provides from launch the
therapy outcomes The remains disease made in real-time. patients. better And working? of information second offer early the in is, the is This tumors majority that could potentially question the it to cycle thus allow changes for provided unanswered to be from therapy more
start to And not emerging surgery beginning of and a personalized a that we whose they decisions approach whether earlier of the upon requiring upon They without allow of of the Chronix Our surgical need answer and – blood-only help patents patients alone. monitoring treated can acquired tumors majority patients resected specimen MRD testing, the test is disease These time adequately to tumor, initiation The meaning is of resection prior can methods complicated a which knowledge have tests monitoring. patients. always tissue only individual are to option solid therapy the these be execute to in tumor extra interpretations companies this genome. require serve residual removed When today sequencing happen not takes proprietary year, by results and they therapy available. serve Biomedical acquired be are because treatment no the immediate offer of them. genomic were patients identify tumor and This to since allows tumor of tests minimal testing without fact surgically. to we subset can patients to
research be U.S. to And we XXXX. therapy monitoring European tech DetermaCNI of for is the completing launched Our use. product, will transfer Union QX in the in
need tissue, test physicians tumor resected does only, of an offering a option Our patients they blood-based the for is not majority that serve. and
tissue exciting global clinical can efforts billion very cycle X its in results. opportunity In second monitoring DetermaCNI therapy fact, to weeks under can for belt. billion development at more therapy chemotherapy, Oncocyte imaging or tumor progression in results With solve our disease a participate the on the X or on market. This targeted now phase, only requirement getting is meaningful provide utility studies our DetermaIO immunotherapy, to now launch the focus we MRD problem, provides of before not also
that of very physicians Taking can in DetermaCNI to say we as So patient's to and this, treat focused compliment deliver next Bottom excited four U.S. despite line we've the facing a patients only our journey. robust comprehensive full the test and to market I'm challenges current quarters. market question in set capability now to that to of stayed a in rounds represents the is portfolio the and poised closer Europe. the whole, are answer tests the to over throughout every offering our the monitoring move them who pandemic, of out
capabilities. drought year. large these important during on with metric revenue market tests With rapid unique the year launch growth in our see the believe we envisioned be now we next on watching were market The our the adoption. entering Oncocyte our opportunities Ultimately, when most gaining laid market And the which very all is momentum, strategy. we’ll portfolio compelling proprietary we'll out current within will launches reimbursement, product be current based we their
as to revenue the is we Oncocyte solid can be there'll information the physicians. we treating found full While along them, the of tests, deliver for journey comprehensive launched individual growth force in strategy
enthusiastic now thus, immune the CLIA We've Last beginning the go-to-market two and less vision. across creation strategy. years, product we proprietary four for updates launch every ahead. we've for that now selected the had incredible is known we test. only in technology potential validations to DetermaIO, every today molecular therapy. clinical supporting tested internally, patients than over about X,XXX validation completed completed and diagnostic potential clinical analytical some outperformed in DetermaIO for solid we stages, of validated That's remain some way clinical our including the the evaluations, the Our In other we randomized And strategy tumors. incredibly value major we've week, change behind time patients long-term on the the study, and reproducibility, announced
tumor I'm breast, types, benefit to DetermaIO, lung, very DetermaIO flagship that and test immune some inform have in of care evaluating missed bladder optimal immunotherapy. even has the market, which today, been only standard immunotherapy. test strategy from In types, IC identify in responsers immunotherapy in the for S head-to-head and who DetermaIO discuss who million during unmet PD-LX both patients need tumor eligible therapy the better and U assesses the benefited consistently current the can use critical tumor to in multiple a of clinical comprehensively cancers, is to would the for identified excited test first including than treatment more X annually alone. launch renal studies, across the from patients comparisons the the patients our clinical by product, microenvironment and clinical patients So immune identifying addresses
updates now foundation physicians quarters, presented we pan-immunotherapy used built pan-cancer the Over shared to by that we And a of believe as be we DetermaIO data and clinical the solid various we test. few foundation at for potential strong past conferences. incredibly a on
have with out prior and clinical in to sites program as roll partnered is our the initially with successfully part test study Oncocyte strategy that on tests access an of of participated efforts. physicians Our early
successful still the on targets days allow to precious sample early than deliver sample the of rapid turnaround sequencing provide use conserve industry turnaround of us tumor XX comprehensive sample our This DetermaIO. next-generation gene less status promise processing tissue the using same our based of to compliance. on will for and After will a utilize in tissue meet genomic tests while that logistics immune and processes we time understand DetermaTx, information maintaining have will under strict DetermaTx synoptic their we while immune decision lowest HIPAA the for LCD needs ensure requirements roll comprehensive a Medicare. program, the DetermaIO patient. optimized, options profiling therapy and for or the been physician then the current local to out delivering targeted to and optimize During we we’ll EAP access our inform coverage launch to a fall XXX
QX our DetermaTx treatment expect generating the its giving to patients. in To options be as in therapy the us product large provider in physicians we us market for and complete their XXXX. launch for we'll And various this exciting comprehensive second and DetermaCNI half of research $X XXXX. of differentiated combination, compliment U.S. test menu, close So billion a predictive watch to available as will answers to with the revenue decision cancer most of establish access to use a test
U.S. be research managing clinical the in cancer. efforts pharma I attracting patients generate in efforts and registry test for the currently providing real-world initial for and researchers. will as to is the via and said, on Our evidence is being this trials, Europe already DetermaCNI, pharma test our for treated for benefit available trials of
the for testing. appreciate researchers has therapy the running we're enthusiastic the So monitoring feedback We over early trials. and of report need solid studies as tissue need ASCO as they the or about blood-only to in DetermaCNI in and without X,XXX costly and from very at immunotherapy solid very EU forward remain tumors across genome solution oncologists now various out targeted We been for the patients have and look several XXXX.
just well early our beginning for patients growth cancer that for patients, we had rapidly our DetermaRx of patients high for have in at XX% than which they to in test to of cases years. samples, increase pandemic, I'm are XX%. launching DetermaRx, within This proud results the stage survival to for risk lose high run team of or their lives. Oncocyte's But patients’ on this life Despite risk five-year surgeons cancer. have of idea unprecedented track are our to their of will their Since Without samples rate year challenges, XXX had is a five we've the over DetermaRx now. important the lung test essence Moving spring no the expected tests stage on say receiving to ago, approximately to was DetermaRx. when the many X,XXX lung well surgical over boards, getting over chemo had market. XXXX these from for mission. been year-over-year ahead and Instead, XXXX of us. cancer managing volume based year saving Simply bring access at patients put, we a early these the close action, of is lung XX% the over of XXX% we more to deemed suites is above recurrence test launched what these
in the metrics environment. We we use judge to straight continue experience key to to current adoption
QX in surgeries And the Delta more on number solid. into Our but Mitch surge, which have hospitals particularly will meaningful early where our of in key growth the is impacted significant dramatically new adoption. we details, go strong physicians in this stage diagnoses board and was and in the area given headwinds has from
lung XX% one XXXX. of early diagnosed study cancer fact, In surgeries a reduction and summer in the cases stage showed through
end October, our encouraged push. While closing steady the in which we in surgical were year really in summer good to-date a is a uptick our sign slow in showed sample cases, down believe we volume and September, for had volume by a month largest
DetermaRx Our poised experience returned and from value surge as the test to emerged growing our patients install surgeries volume early Delta has to base and states screenings us we pre-pandemic speaks to growth of brings to strong and physicians levels. the ordering
access I’ll our to monitor close Next our about we per is alone TheraSure briefly blood-based a this the which for approximately opportunities, our acquisition, $X,XXX of patient established billion early treatment. United transition the solid $X,XXX of monitoring. the organ test very per growth also Transplant reimbursement stand acquired of between in States. patented transplant, Biomedical. Chronix $X patients acquisition rejection in to test Monitor test talked with market emerging This to Through large earlier from cancer and U.S. DetermaCNI We
issued, patent transplant of a the revenue very our and We monitoring market second is LDT CLIA our into differentiator rejection. entry product needed we detection now IP organ lab. TheraSure which issuance compliments method for our the versus patent of stream for use with competing out for rejection, of next-generation to monitor a first technique our gave molecular digital revenue recurring represents this sequencing starting as support modality PCR very U.S. transplant covering us a absolute IP U.S. the patent testing our quantification, U.S. repeat new the an large Oncocyte. the allograft Recently opportunity Nashville Given received our for important This solid of in in methods. have both for around components out the
is how So the broadest organs. test across TheraSure differentiated? offers First, our transplanted application
indication While is the we for have current test indication the kidney, in transplants. with heart TheraSure liver monitoring two a volume organs largest transplanted, and only
dosing indication in also will the suppress profit critical sensitivity therapy can We timely rejection, to early offer which time greater change the a turnaround fastest rejection. and for and of
donor offers allows reviewed identify rejection, to as organ publications cell to the is sensitivity early for all utility death peer onset greater biomarker rejected. derived test in soon have that usefulness validated clinical time. and our cell-free test over to of studies transplant health DNA Over numerous for of which our Additionally, a signs providing monitoring non-invasive be under absolute XX quantification, a of or longitudinal assess immunosuppression, rejection,
However, American differ DNA. in of have for cost speed been Data These prestigious method methods most cell-free as published Journal to and and derived use and that compared measure our journals, identifies results the in of others. digital donor published payers the date to is in other other accuracy, including Transplantation, effective fastest effectiveness, PLOS technologies Medicine, turnaround. PCR
away coverage Importantly, performance in three here solid titled, digital for the for allograft monitoring. the U.S. policy and a chronic of commercialization transplant for validation the transplant on is peer This paves citing it’s huge test chronics rejection in organ recent reviewed PCR reimbursement methods cites we the in solid publications organ our as and monitoring CMS believe rejection, of technology,
QX, U.S. to in an LVT launch the XXXX. of the end We’re on fast by now track a
to gain begin our Monitor reimbursement we Center attractive about is offered current efforts which our quarter, new access the Transplant test currently for of to Europe So details we represents another plans And Medicare unveiled the Services. untapped. TheraSure by last the the in Europe. market, can
our to for We’re of local now governments reimbursement with ahead in launch moving Germany. rapidly work XXXX
same in potential of differentiated deliver and loss about enthusiastic more recipients surveillance day provide cell-free quantitative for premature specific, digital incredibly follow-up, re turnaround summary, precise, cost-effective donor the time to of In need transplant management. of our a resulting is We’re patient decrease grapple to derived approach cost-effective for information – transplantation. DNA longitudinal important can to a
I’m investors who our development As we have for through our team, look us comprehensive offering. supported of excited our very the phase forward,
to We’re billion. exit of continuing compelling and and the take momentum testing fastest of of customer to in our infrastructure of solid our And rapid positions growing XXXX toward and deliver In molecular of to advantage the year have oncology. powerful the will Board molecular progress, well launching some over each market we’ll with area a $XX make thought progress portfolio on order diagnostic experience. test assets growth. product areas combined opportunity of a it a proprietary large we solidify a with a of to markets time promises Senior and was XXXX be best-in-class expansion to full Management goal
with EXACT essential. growth Oncocyte will us period of Genomic Operating Officer Chief as flawless positions and execution recent and Gisela are Sciences, to leadership history and Roche Genentech, the in where upcoming talent operations world-class in experience Our team. strategy, our industry solid Health Paulsen about be Her appointment brings
contributions Mitch? turn say we incredibly particularly is by oncology challenges have of the major be financials. required incredible to by Mitch pandemic. of the At the to out beyond, Oncocyte as team, the to and commitment I this United incredible to potential programs look we responded can amazed has relentless over to and our to on believes convict and our organization keeping Levine the patients in conviction, all Europe. forward their our the And team the build that menu call treatment the review States team excited of have fundamentals dedication deliver her to I’d point, the transform to how I’m with like during proud track. We’re decisions her to to physicians Continue unwavering on in evidence. and
